<div id="readability-page-1"><div> <div> Faruqi &amp; Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Immutep To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Immutep between March 24, 2025 and March 12, 2026 and would like to discuss your legal rights, call Faruqi &amp; Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information], /PRNewswire/ -- Faruqi &amp; Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Immutep Limited (&#34;Immutep&#34; or the &#34;Company&#34;) (NASDAQ: IMMP) and reminds investors of the July 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. </div> </div><div> <div> Faruqi &amp; Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or concealing material adverse facts concerning the efficacy and safety of its TACTI-004 Phase III clinical trial study. Particularly following positive top-line results from Immutep's prior TACTI-002 and INSIGHT-003 studies. Further, defendants announced in a Form-K filed with the SEC in January 30, 2026, that the trial was exhibiting &#34;strong operational progress&#34; and the planned interim futility analysis remained &#34;on track for the first quarter of 2026.&#34; In truth, Immutep was aware of or was reckless, based on its access to internal clinical data, analyses, and reports concerning the TACTI-004 trial and its planned interim futility evaluation, that then-existing information materially increased the risk that the study would fail to meet its primary efficacy and/or safety endpoints. On March 13, 2026, Immutep issued a press release &#34;announcing that the Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1(st) line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol.&#34; In addition, the press release stated that, &#34;based on its review of the available safety and efficacy data, the IDMC recommended that the trial be discontinued for futility&#34; and that, accordingly, &#34;enrolment in the study will be halted and the Company will implement an orderly wind down of the study, including appropriate patient follow up and site close out in accordance with regulatory and ethical obligations.&#34;On this news, Immutep's American Depositary Receipt (&#34;ADR&#34;) price fell $2.28 per ADR, or 82.6%, to close at $0.48 per ADR on March 13, 2026.The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi &amp; Faruqi, LLP also encourages anyone with information regarding Immutep's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.To learn more about the Immutep class action, go to www.faruqilaw.com/IMMP or call Faruqi &amp; Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).Follow us for updates on LinkedIn, on X, or on Facebook.Attorney Advertising. The law firm responsible for this advertisement is Faruqi &amp; Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.SOURCE Faruqi &amp; Faruqi, LLP<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE0Jk5ld3NJdGVtSWQ9Tlk1OTE4NCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTQxMDE5UFJfTkVXU19VU1BSX19fX19OWTU5MTg0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE0Jk5ld3NJdGVtSWQ9Tlk1OTE4NCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTQxMDE5UFJfTkVXU19VU1BSX19fX19OWTU5MTg0"/></div> </div></div>

IMMP

Faruqi & Faruqi, LLP is investigating potential claims against Immutep Limited (NASDAQ: IMMP) and reminds investors of the July 6, 2026 deadline to seek lead plaintiff status in a federal securities class action. The complaint alleges that Immutep made misleading statements regarding the efficacy and safety of its TACTI-004 Phase III clinical trial, which was ultimately discontinued due to futility. Following this announcement, Immutep's ADR price fell by 82.6%. Investors who suffered losses are encouraged to contact the firm for legal options.

10:19 ETIMMP INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Immutep (IMMP) Investors of Securities Class Action Deadline on July 6, 2026